The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Alunbrig Beats Xalkori in Front-Line NSCLC: Takeda
Takeda Pharmaceutical’s ALK inhibitor Alunbrig (brigatinib) significantly extended progression-free survival (PFS) versus Xalkori (crizotinib) in a front-line setting for ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), according to an interim PIII data. Alunbrig racked up the statistically…
To read the full story
Related Article
- Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
September 27, 2018
- Takeda’s Ariad Acquisition Completed
February 20, 2017
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…